Investigation of the effect of Selenium in beta thalassemia major

The effect of supplementation with Selenium on serum inflammatory factors of beta thalassemia major patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180603039959N3

Enrollment

Registered

2023-02-06

Start date

2023-02-21

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia major. Beta thalassemia

Interventions

Intervention group: 42 patients with thalassemia major or intermedia are selected according to the study criteria. Selenium tablets of 200 µg are given to the patients daily for one month after receiv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having thalassemia major or intermedia Healthy liver and kidney function

Exclusion criteria

Exclusion criteria: Severe heart, liver or kidney failure History of chemotherapy Diabetic patients Patients with fever and acute and chronic inflammatory infections Taking any selenium supplement for at least two months before the study

Design outcomes

Primary

Measure	Time frame
TNF-alpha (TNF-a). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure TNF-a.;IL-6. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-6.;IL-1b. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-1b.;IL-2. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-2.;C-reactive protein (CRP). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure CRP.;Neutrophil to lymphocyte ratio (N/L Ratio). Timepoint: Start of treatment, one month after treatment. Method of measurement: The ratio of neutrophils to lymphocytes (N/L ratio) is obtained from the results of complete blood count (CBC).;The antioxidant superoxide dismutase (SOD). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure SOD.;Thyroid Stimulating Hormone (TSH). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure TSH.;Triiodothyronine (T3). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure T3.;Thyroxine (T4). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure T4.	—

Measure

Time frame

TNF-alpha (TNF-a). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure TNF-a.;IL-6. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-6.;IL-1b. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-1b.;IL-2. Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure IL-2.;C-reactive protein (CRP). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure CRP.;Neutrophil to lymphocyte ratio (N/L Ratio). Timepoint: Start of treatment, one month after treatment. Method of measurement: The ratio of neutrophils to lymphocytes (N/L ratio) is obtained from the results of complete blood count (CBC).;The antioxidant superoxide dismutase (SOD). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure SOD.;Thyroid Stimulating Hormone (TSH). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure TSH.;Triiodothyronine (T3). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure T3.;Thyroxine (T4). Timepoint: Start of treatment, one month after treatment. Method of measurement: ELISA method is used to measure T4.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKambiz Davari

Ahvaz University of Medical Sciences

Kdatzums@yahoo.com+98 41 3336 1658

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026